Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kubota Pharmaceutical Holdings Co (TSE:4596) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kubota Pharmaceutical Holdings Co's Enterprise Value for the quarter that ended in Jun. 2026 was 円6,921.27 Mil.
Kubota Pharmaceutical Holdings Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-729.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kubota Pharmaceutical Holdings Co EV-to-EBIT Related Terms
Kubota Pharmaceutical Holdings Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kubota Pharmaceutical Holdings Co EV-to-EBIT Chart
TSE:4596 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Kubota Pharmaceutical Holdings Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kubota Pharmaceutical Holdings Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kubota Pharmaceutical Holdings Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kubota Pharmaceutical Holdings Co's EV-to-EBIT falls into.
Kubota Pharmaceutical Holdings Co's current Enterprise Value is 円9,686.29 Mil.
Kubota Pharmaceutical Holdings Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-729.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kubota Pharmaceutical Holdings Co (TSE:4596) has a EV-to-EBIT of -13.28 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kubota Pharmaceutical Holdings Co and its competitors. According to the industry distribution chart, Kubota Pharmaceutical Holdings Co ranks #999999 out of 380 companies in the Biotechnology industry.
Is Kubota Pharmaceutical Holdings Co's EV-to-EBIT too high?
Kubota Pharmaceutical Holdings Co's current EV-to-EBIT is -13.28. Based on the distribution chart, Kubota Pharmaceutical Holdings Co ranks #999999 out of 380 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kubota Pharmaceutical Holdings Co has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kubota Pharmaceutical Holdings Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kubota Pharmaceutical Holdings Co ranks #999999 out of 380 companies for EV-to-EBIT. This places Kubota Pharmaceutical Holdings Co in the lower half of its industry. The industry median EV-to-EBIT is 15.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.92, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kubota Pharmaceutical Holdings Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kubota Pharmaceutical Holdings Co's current EV-to-EBIT is -13.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kubota Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Kubota Pharmaceutical Holdings Co (TSE:4596) is currently considered Significantly Overvalued. The stock's GF Value™ is 円21.04, compared to a current price of 円69.00 — trading 227.9% above its estimated fair value. The current EV-to-EBIT is -13.28. Kubota Pharmaceutical Holdings Co's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kubota Pharmaceutical Holdings Co (TSE:4596), the current EV-to-EBIT is -13.28 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kubota Pharmaceutical Holdings Co (TSE:4596) Overvalued in 2026?
Based on GuruFocus' analysis, Kubota Pharmaceutical Holdings Co stock appears to be overvalued.
The current stock price of 円69.00 is trading 227.9% above its estimated GF Value™ of 円21.04.
GuruFocus considers Kubota Pharmaceutical Holdings Co to be Significantly Overvalued.
Key valuation signals for TSE:4596:
EV-to-EBIT: -13.28
GF Value™: 円21.04 vs. price of 円69.00 (227.9% above fair value)
No single metric tells the full story. See the TSE:4596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kubota Pharmaceutical Holdings Co Ltd is a Japanese company providing portfolio of drugs and devices to preserve and restore millions of people. It identifies and develops therapeutics to treat the opthalmic disorder and operations incidental or related thereto. Its pipeline products include VCM-Emixustat HCI, Lanosterol and Optogenetics.
37GF Score
Get the complete analysis for TSE:4596
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4596 has been successfully added to your 
